156 related articles for article (PubMed ID: 21257151)
1. Pre-seasonal treatment with topical olopatadine suppresses the clinical symptoms of seasonal allergic conjunctivitis.
Shimura M; Yasuda K; Miyazawa A; Otani T; Nakazawa T
Am J Ophthalmol; 2011 Apr; 151(4):697-702.e2. PubMed ID: 21257151
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and artificial tears in seasonal allergic conjunctivitis.
Kamis U; Ozturk BT; Ozkagnici A; Gunduz K
Acta Ophthalmol Scand; 2006 Feb; 84(1):148-9. PubMed ID: 16445458
[No Abstract] [Full Text] [Related]
3. [First Hungarian report of olopatadine eyedrop therapy in children and adults suffering from seasonal allergic conjunctivitis].
Endre L; Hidasi V
Orv Hetil; 2006 Sep; 147(36):1741-3. PubMed ID: 17087018
[TBL] [Abstract][Full Text] [Related]
4. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell.
Leonardi A; Quintieri L
Expert Opin Pharmacother; 2010 Apr; 11(6):969-81. PubMed ID: 20307221
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
Borazan M; Karalezli A; Akova YA; Akman A; Kiyici H; Erbek SS
Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge.
Abelson MB; Spangler DL; Epstein AB; Mah FS; Crampton HJ
Curr Eye Res; 2007 Dec; 32(12):1017-22. PubMed ID: 18085465
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
Avunduk AM; Tekelioglu Y; Turk A; Akyol N
Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412
[TBL] [Abstract][Full Text] [Related]
8. Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice.
Villareal AL; Farley W; Pflugfelder SC
Eye Contact Lens; 2006 Dec; 32(6):272-6. PubMed ID: 17099387
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of olopatadine 0.01% combined fluorometholone 0.1% treatment versus olopatadine 0.01% combined ketorolac 0.4% treatment in patients with acute seasonal allergic conjunctivitis.
Celik T; Turkoglu EB
Curr Eye Res; 2014 Jan; 39(1):42-6. PubMed ID: 24074291
[TBL] [Abstract][Full Text] [Related]
10. Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis.
Abelson MB; Gomes PJ; Vogelson CT; Pasquine TA; Turner FD; Wells DT; Robertson SM
Curr Med Res Opin; 2005 May; 21(5):683-91. PubMed ID: 15969867
[TBL] [Abstract][Full Text] [Related]
11. Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing.
Abelson MB; Gomes PJ
Expert Opin Drug Metab Toxicol; 2008 Apr; 4(4):453-61. PubMed ID: 18433347
[TBL] [Abstract][Full Text] [Related]
12. Olopatadine for allergic conjunctivitis.
Med Lett Drugs Ther; 1997 Nov; 39(1014):108-9. PubMed ID: 9398823
[No Abstract] [Full Text] [Related]
13. [Effectiveness of olopatadine therapy in seasonal allergic conjunctivitis].
Turlea M; Mârza F; Turlea C
Oftalmologia; 2009; 53(4):67-71. PubMed ID: 20361653
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.
Greiner JV; Udell IJ
Clin Ther; 2005 May; 27(5):568-77. PubMed ID: 15978305
[TBL] [Abstract][Full Text] [Related]
15. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans.
Leonardi A; Abelson MB
Clin Ther; 2003 Oct; 25(10):2539-52. PubMed ID: 14667955
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
Abelson MB; Greiner JV
Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
[TBL] [Abstract][Full Text] [Related]
17. Olopatadine hydrochloride inhibits capsaicin-induced flare response in humans.
Shindo M; Yoshida Y; Yamamoto O
Pharmacology; 2011; 87(3-4):152-4. PubMed ID: 21346393
[TBL] [Abstract][Full Text] [Related]
18. The effects of the nasal antihistamines olopatadine and azelastine in nasal allergen provocation.
Pipkorn P; Costantini C; Reynolds C; Wall M; Drake M; Sanico A; Proud D; Togias A
Ann Allergy Asthma Immunol; 2008 Jul; 101(1):82-9. PubMed ID: 18681089
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate.
Aguilar AJ
Acta Ophthalmol Scand Suppl; 2000; (230):52-5. PubMed ID: 11057352
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis.
Yaylali V; Demirlenk I; Tatlipinar S; Ozbay D; Esme A; Yildirim C; Ozden S
Acta Ophthalmol Scand; 2003 Aug; 81(4):378-82. PubMed ID: 12859265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
